This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Browse our events, training, articles and people by topicclose

Popular sectors

A - Z

Browse Topics apps close
search

Cell & Gene Therapy

Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Cell and Gene Therapies: Viral and Non-Viral Vector Manufacturing - WHITEPAPER

ArticleImage

Download the exclusive whitepaper

In 2018 there were a total of 906 regenerative medicine companies in operation globally, operating over 1000 active clinical trials, 70% of which deployed vectors in the products under investigation. In 2018 two FDA approved CAR-T cancer cell therapy products that utilize lentivectors in their manufacture achieved expanded market approval, and one gene therapy based on an AAV vector achieved a first market approval in the US, leading to increased demand for the manufacturing of these vectors.

This whitepaper explores:

  • Vector manufacturing capacity crunch

  • Challenges and progress in viral vector bioprocessing

  • A role for automation and machine learning

  • The future of lentiviral vectors

  • Promising emerging non-viral approaches


To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.

有任何问题或有兴趣赞助砰的一声吗ure content? Email andrew.burrows@informa.com.

ABOUT THE AUTHOR: David Orchard-Webb, PhD, is a freelance consultant and medical/biotech writer.

Log in or create an Informa Connect account to access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.

Copyright ©2020金宝搏App下载